Semaglutide
GLP-1 analog / Ozempic / Wegovy / Rybelsus
- Peptide length
- 31 amino acids
Acylated peptide analog
Open the sources to check how the studies were done and what they can support.
A long-acting GLP-1 receptor agonist used in regulated medicines. Oral and injectable products have different formulations and labeled uses.
- Family
- Incretin analog
- Research target
- GLP-1 receptor
- Molecular form
- Acylated peptide analog
- Formula reported by the source
- C187H291N45O59
What to know about the research
Use the current label for the exact product and population. A trial of a finished medicine does not establish equivalence for a research vial or semaglutide salt.
Check the exact compound
Confirm the modified sequence, acylation, counterion and formulation. Semaglutide base and salt forms must not be treated as interchangeable.
What supports this entry?
1 of 3 summary statements linked to checked source passages.
These are selected references, not a complete review of the literature. Source checks were assisted by AI and have not received independent expert review.
Research stage, study quality and regulatory status answer different questions. A study card does not establish treatment benefit or approval.
Check the overview statementSource checked
A long-acting GLP-1 receptor agonist used in regulated medicines. Oral and injectable products have different formulations and labeled uses.
Prescribing information, sections 1, 3, 11 and 12.1; PDF pages 1, 5, 20–21
- Scope is the named finished products and formulations in this label, not an unidentified research preparation.
No study details have been extracted for this exact entry yet. This does not mean that no studies exist. Open the references and check the exact material.
The remaining statements still need individual source mapping. Use the original references when checking a claim.
How we prepare and correct these entries